The week in pharma: action, reaction and insight – week to May 16

By Barbara Obstoj-Cardwell. Editor

Pharmaceutical share prices fell last Monday, after US President Donald Trump vowed to reduce drug prices in the USA by as much as 80%, and then released more details of his plan. On the research front, Belgian biotech iTeos Therapeutics released disappointing Phase II data on its belrestotug + dostarlimab, leading to the termination of the TIGIT program with UK pharma major GSK. Travere Therapeutics’ shares dropped despite the US Food and Drug Administration (FDA) accepting its Filspari supplemental new drug application (sNDA), as the agency said it would hold an advisory committee (AdCom) meeting. US biopharma company Biohaven also hit a snag with the FDA, which has delayed its approval decision on its ataxia candidate troriluzole. Also of note, BioMarin Pharmaceuticals disclosed plans to acquire fellow American drugmaker Inozyme, along with its enzyme replacement therapy INZ-701, for $270 million.

Previewing Trump EO: MFN Exposure Quantified